On July 10, shares of Danish pharmaceutical giant Novo Nordisk surged more than 5% in pre-market trading, driven by sustained strong demand for its weight-loss drug Wegovy and diabetes treatment Ozempic. Recent sales data show that these GLP-1 receptor agonist-based medications are experiencing overwhelming global demand, particularly in the U.S., where prescription volumes and patient interest continue to rise. Additionally, the company has raised its full-year 2024 revenue and profit guidance, further boosting investor confidence.Analysts note that Novo Nordisk’s leadership in the GLP-1 drug class is translating into significant financial advantages. With rising global prevalence of obesity and type 2 diabetes, demand for such innovative therapies is expected to grow steadily. The company is also actively expanding production capacity to alleviate supply constraints and plans to increase Wegovy output several-fold over the next few years.The pre-market rally reflects market recognition of Novo Nordisk’s long-term growth potential. Despite its valuation already trading at historically high levels, the company’s robust fundamentals and clear growth trajectory continue to position it as a premium asset in the healthcare sector. Investors are widely anticipating another strong performance in its upcoming quarterly earnings report.
7月10日盘前交易时段，丹麦制药巨头诺和诺德（Novo Nordisk）美股股价大涨超5%，主要受其减肥药物Wegovy和糖尿病药物Ozempic持续强劲需求的推动。近期公布的销售数据显示，这两款基于GLP-1受体激动剂的药物在全球市场供不应求，尤其在美国，处方量和患者需求持续攀升。此外，公司上调了2024年全年营收和利润预期，进一步提振投资者信心。分析师指出，诺和诺德在GLP-1类药物领域的领先地位正转化为显著的财务优势。随着肥胖症和2型糖尿病在全球范围内的发病率不断上升，市场对这类创新疗法的需求预计将持续增长。同时，公司还在积极扩大产能，以缓解供应链紧张问题，并计划在未来几年内将Wegovy的产量提升数倍。此次盘前大涨也反映出市场对诺和诺德长期增长潜力的认可。尽管其估值已处于历史高位，但强劲的基本面和清晰的增长路径使其仍被视为医疗健康板块中的优质资产。投资者普遍期待公司在即将发布的季度财报中继续交出亮眼表现。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/15791.html